Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Sen Bernie Sanders (I, Vt) has urged Robert McDonald, secretary of the US Department of Veterans Affairs (VA), to enlist third parties to manufacture the patented hepatitis C drugs in the interest of facilitating cost-effective treatment (http://1.usa.gov/1T1LN0S) for veterans, who are infected at a rate 3 times higher than that of the general US population (http://1.usa.gov/1KK1ZOR). The letter references the drug Solvadi (sofosbuvir), a medication used to treat hepatitis C that is manufactured by Gilead Sciences. The medication is currently priced at $1000 per pill, or $84 000 for a full course of treatment. In his letter, Sanders cited a legal statute that would allow Gilead to seek reimbursement from the VA in federal claims court.
Buchholz L. Senator Urges VA to “Break” Patents for High-Cost Hepatitis C Drugs. JAMA. 2015;314(2):115. doi:10.1001/jama.2015.7534
Customize your JAMA Network experience by selecting one or more topics from the list below.